Valproate - sodium valproate, valproic acid, sold as Epilim and other brands - is an effective treatment for epilepsy, bipolar disorder and migraine prevention. It also causes physical birth defects in roughly one in ten babies exposed in the womb, and neurodevelopmental problems including autism and learning disability in a much higher proportion again. The scale of that harm is unlike anything else in routine prescribing, and the restrictions now attached to it exist because informal warnings failed for decades.
Follow the plan your specialist gave you. This guide contains no doses. Never stop valproate suddenly.
What the risk actually is
Around one in ten babies exposed to valproate in the womb has a major congenital malformation - spina bifida, heart defects, cleft palate, limb and urinary tract abnormalities.
Around three to four in ten have neurodevelopmental problems: developmental delay, lower IQ, autism spectrum disorder, ADHD. These may not become apparent for years.
For comparison, the background risk of major malformation in any pregnancy is around two to three per cent. Valproate multiplies it several times over, and the developmental risk has no real parallel among other anti-epileptics.
Thousands of children in the UK are affected, and an inquiry found that warnings were known about for many years before they reached patients effectively. That history is why the current rules are as firm as they are.
The Pregnancy Prevention Programme
For anyone able to become pregnant, valproate must not be used unless the conditions of a formal programme are met. In broad terms:
- It must not be used at all unless there is no other effective treatment.
- Highly effective contraception is required throughout.
- An annual specialist review is required, with a signed Annual Risk Acknowledgement Form.
- A patient card and warnings on the packaging accompany every supply.
Pharmacies dispense it in the original packaging with the warnings visible, which is why it may not go into a dosette box - see blister packs and dosette boxes.
The newer restrictions, including for men
Following a further review, the MHRA introduced additional measures. Valproate should not be started in anyone under 55, male or female, unless two specialists independently agree there is no other effective or tolerated treatment and document that agreement.
The extension to men follows a study suggesting a possible increased risk of neurodevelopmental disorders in children fathered by men taking valproate. The evidence is less certain than for maternal exposure, and the precaution was taken anyway given the history.
Men taking it are advised to use effective contraception during treatment and for a period afterwards, and not to donate sperm.
If you are on valproate and have not had this conversation, ask for a review.
If you are pregnant or might be
Do not stop taking it. Contact your specialist team urgently - the same day.
Stopping an anti-epileptic abruptly risks prolonged seizures, which are dangerous for both mother and baby. The decision has to be made by people who can weigh both sides, and there may be alternatives that can be introduced safely.
Higher-dose folic acid is recommended before conception for anyone on an anti-epileptic - see folic acid, though it does not remove the valproate risk.
Other side effects
Weight gain, hair thinning or texture change, tremor, drowsiness and nausea are common. Our guide to medicines and your weight covers the first.
Seek urgent advice for severe abdominal pain with vomiting, which can indicate pancreatitis; and for jaundice, dark urine, persistent nausea or unusual drowsiness and confusion, which can indicate liver injury or raised ammonia. Both are rare and both are serious.
Liver function and blood counts are monitored, particularly in the first months - see monitoring long-term medicines.
Never stop suddenly
Abrupt withdrawal can provoke seizures, including status epilepticus, even in someone who has been seizure-free for years. Any reduction is planned and gradual with a specialist.
Running out counts as stopping - see ordering repeats and why you cannot just stop some medicines.
Brand consistency matters for valproate, so if your packaging changes, mention it - see why your tablets look different.
Bipolar disorder and migraine
Valproate is also licensed for acute mania and used for maintenance in bipolar disorder, and off-label for migraine prevention.
The restrictions apply regardless of why it is prescribed. For migraine in particular there are several alternatives - propranolol, amitriptyline, candesartan and the newer CGRP treatments - and it is difficult to justify valproate for headache prevention in anyone able to become pregnant. Our guide to migraine medicines covers the options.
If you were affected
Families affected by valproate exposure have organised support and advocacy, and there are recognised routes for reporting historical harm through the Yellow Card scheme - see if you think a medicine has harmed you.
See also Levetiracetam: Uses and the Mood Side Effects, and the Conditions section for more on what medicines are prescribed for.